Lung Neoplasm

Oncology·MeSH: Lung Neoplasms

Prevalence

30.0 / 100K

7 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(7)

Drug	Company
Acetaminophen	Merck & Co., Inc. (MRK)
Datopotamab Deruxtecan	Merck & Co., Inc. (MRK)
H1 receptor antagonist	Merck & Co., Inc. (MRK)
H2 receptor antagonist	Merck & Co., Inc. (MRK)
MK-1084	Merck & Co., Inc. (MRK)
Patritumab deruxtecan	Merck & Co., Inc. (MRK)
Taletrectinib	Nuvation Bio Inc. (NUVB)

Compare drugs

Acetaminophen vs Datopotamab Deruxtecan Acetaminophen vs H1 receptor antagonist Acetaminophen vs H2 receptor antagonist

Frequently asked questions

How many drugs are in development for Lung Neoplasm?

BioSniper tracks 7 drugs in development for Lung Neoplasm across 2 companies.

How many clinical trials target Lung Neoplasm?

There are 2 clinical trials targeting Lung Neoplasm tracked by BioSniper.

What is the prevalence of Lung Neoplasm?

The estimated prevalence of Lung Neoplasm is approximately 30.0 per 100,000 population.

Deep-dive into Lung Neoplasm

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Lung Neoplasm — Drugs in Development & Clinical Trials | BioSniper